H.C. Wainwright lowered the firm’s price target on IGM Biosciences to $11 from $12 and keeps a Neutral rating on the shares following the Q2 report. The firm cites higher long-term operating expenses for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences price target lowered to $24 from $25 at Truist
- IGM Biosciences price target raised to $25 from $20 at Wedbush
- IGM Biosciences price target raised to $12 from $11 at JPMorgan
- IGM Biosciences reports Q2 EPS (79c), consensus (4c)
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update